In the next five years, the company will further implement the R&D strategy of “innovation first, innovation while imitation”. Adhere to capital investment as the basis, talent development as the support, and system construction as the guarantee, constantly improve the quality and level of R&D projects, and find a path of sustainable innovation and development that is in line with the actual situation of the group, so that “innovation” truly becomes the core of the group source of power for development.

The company will further increase investment in R&D and strive to account for more than 8% of sales revenue each year to lay a strong material foundation for innovation; it will continue to gather and cultivate top talents, strengthen the construction of talent echelons, and focus on talent training. Build a high-quality scientific research team through “learning and mentoring”. By improving diversified distribution methods such as equity incentives, we will create a good atmosphere for innovation and provide strong intellectual support for innovation; we must further improve the innovation system, build an innovation platform, create a highland for corporate innovation, and provide a strong guarantee for sustainable innovation and development.

(1) Selection of R&D direction
Focusing on original drugs, taking into account the research of me-too and me-better innovative drugs, we select generic drugs that can become the first generic drugs to be launched for rapid imitation.